At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 410 enrolled
Drug / intervention
Herpes zoster vaccine GSK1437173A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older
In Brief
A Phase 2 clinical trial evaluating Herpes zoster vaccine GSK1437173A and Placebo for Herpes Zoster. Completed, enrolled 410 participants across 12 sites in 3 countries.
Detailed Summary
The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesCzechia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartJan 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedDec 5, 2008
Enrollment StartJan 12, 2009
Primary CompletionJul 2, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.6 years ago
Interventions
Herpes zoster vaccine GSK1437173Abiological
2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
Placebobiological
2 vaccinations at Months 0 and 2 with placebo